BJORNSON, KYLA,CANALES, EDA,COTTELL, JEROMY J.,KARKI, KAPIL KUMAR,KATANA, ASHLEY ANNE,KATO, DARRYL,KOBAYASHI, TETSUYA,LINK, JOHN O.,MARTINEZ, RUBEN,PHILLIPS, BARTON W.,PYUN, HYUNG-JUNG,SANGI, MICHAEL
申请号：
PE0025872014
公开号：
PE02042015A1
申请日:
2013.07.02
申请国别(地区):
PE
年份:
2015
代理人:
摘要：
Relates to compounds of formula (i) wherein X, u, L, T, M, a, Q, R1, R3, R4, R5, J, e and G are as defined in the description.Preferred compounds are: (3aR, 10s, 11S, 7S, 12R, 24ar) - 7 - Tert Butyl N - [(1R, 2R) - 2 - (difluorometil) - 1 - (1 - {[} metilciclopropil) Carbamoyl] sulfonyl] ethyl cyclopropyl - 11 - 16 - methoxy - 5.8 - [- 1,2,3,3a, 5,6,7,8,11,12,20,21,22,23,24,24a - hexadecahidro - 10h - 9:12 - metanociclopenta 1,10,3,6 [18,19] [b] [11,12] dioxadiazaciclononadecino - quinoxalin - 10 - carboxamide among others.It also relates to a Pharmaceutical composition. These compounds are inhibitors of hepatitis C virus being useful in the treatment of hepatitis C virus infectionSE REFIERE A COMPUESTOS DE FORMULA (I) DONDE X, U, L, T, M, A, Q, R1, R3, R4, R5, J, E Y G SON COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: (3aR,7S,10S,11S,12R,24aR)-7-TERT-BUTIL-N-[(1R,2R)-2-(DIFLUOROMETIL)-1-{[(1-METILCICLOPROPIL)SULFONIL]CARBAMOIL}CICLOPROPIL]-11-ETIL-16-METOXI-5,8-DIOXO-1,2,3,3a,5,6,7,8,11,12,20,21,22,23,24,24a-HEXADECAHIDRO-10H-9,12-METANOCICLOPENTA[18,19][1,10,3,6]DIOXADIAZACICLONONADECINO[11,12-b]QUINOXALIN-10-CARBOXAMIDA ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL VIRUS DE LA HEPATITIS C SIENDO UTILES EN EL TRATAMIENTO DE UNA INFECCION POR VIRUS DE HEPATITIS C
